News

Dosing Paused in Phase 2 Branaplam Trial Due to Possible Side Effects

Due to possible side effects, dosing is being paused in the Phase 2 VIBRANT-HD clinical trial of oral branaplam (LMI070) in adults with Huntington’s disease. A scheduled assessment found “early signs” that “branaplam might be causing peripheral neuropathy,” a condition marked by pain or numbness in the extremities caused by damage…

Case Study: Late-Onset Huntington’s Presents Like Parkinson’s Disease

A 56-year-old man with undiagnosed late-onset Huntington’s disease presented with Parkinson’s disease-like symptoms, including bradykinesia, or slowness of movement, a case study reported. He was correctly diagnosed after clinicians learned of a family history of Huntington’s and ordered genetic testing. Given the diagnosis, the researchers recommended that Huntington’s disease…

Long-term Trials of Exercise for Huntington’s Patients Feasible

Long-term trials of interventions to promote physical activity for people with Huntington’s disease are feasible, with a “nested trial” approach that assigns some patients already taking part in an observational study to an activities group while others serve as controls, a study reported. The yearlong effort was designed as a…